注射用尤瑞克林治疗不同病因分型脑梗死的疗效观察

目的 观察注射用尤瑞克林治疗急性脑梗死的临床疗效及安全性.方法 选择住院的缺血性脑梗死患者164例,按治疗方法 分为治疗组(86例)和对照组(78例),对照组给予阿司匹林抗血小板聚集,按照危险分层应用阿托伐他汀钙,调控血压、血糖、血脂;治疗组在此基础上加用注射用尤瑞克林0.15 PNA单位,加入0.9%氯化钠溶液100 ml,静脉滴注30 min,每日1次,用药10 d.观察两组治疗前、治疗后第15天的神经功能缺损程度,并进行美国国立卫生研究院卒中量表(NIHSS)评分及Barthel指数评定.结果 两组在治疗后第15天NIHSS评分均有改善,Barthel指数有所升高,治疗组较对照组改善明显[(6.67±3.02)分比(7.42±3.02)分;75.36±23.56比68.36±22.36,P＜0.05].这种优势在TOAST分型中的大动脉粥样硬化型更为突出.结论 注射用尤瑞克林在脑梗死的早期即可改善神经功能缺损,提高日常生活能力,且安全性较好,值得临床推广应用.

Effect of urinary kallidinogenase on cerebral infarction with different etiological factor

Objective To investigate the effect and safety of urinary kallidinogenase on acute cerebral infarction.Methods One hundred and sixty-four patients with acute cerebral infarction were randomly divided into two groups:treatment group with urinary kallidinogenase(86 cases)and control group (78 cases).According to Chinese guidelines for prevention and management cerebrovascular disease,two groups were treated with basic therapy,such as antiplatelet,neurologic protection,blood pressure control,and so on.On basis of control group,treatment group Was administrated intravenous injection of urinary kallidinogenase 0.15 PNA U per day for 10 days.The primary efficacy Was evaluated by the National Institutes of Health Stroke Scale(NIHSS)score and Barthel index.Results The score of NIHSS and Barthel index at 15 days after treatment in the treatment group were higher than those in the control group[(6.67±3.02)scores vs(7.42±3.02)scores;75.36±23.56 vs 68.36±22.36,P＜0.05].Urinary kallidinogenase could significantly reduce neurological deficits in big artherosclerosis type by TOAST typing.Conclusion Urinary kallidinogenase may be effective and safe in the treatment of acute cerebral infarction.